Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) PT at $15.86

iTeos Therapeutics, Inc. (NASDAQ:ITOS) has been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $15.86.

A number of brokerages recently weighed in on ITOS. Leerink Partnrs downgraded shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. HC Wainwright downgraded shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $15.00 to $8.00 in a research note on Tuesday, May 13th. Finally, Wedbush downgraded shares of iTeos Therapeutics from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $10.00 to $12.00 in a research note on Wednesday, May 28th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS opened at $10.07 on Thursday. The company’s 50-day moving average is $9.04 and its 200 day moving average is $7.75. The company has a market capitalization of $385.38 million, a P/E ratio of -3.31 and a beta of 1.49. iTeos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. As a group, research analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Transactions at iTeos Therapeutics

In other news, Director David Hallal sold 38,228 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michel Detheux sold 43,883 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the completion of the sale, the chief executive officer directly owned 153,903 shares in the company, valued at approximately $1,542,108.06. The trade was a 22.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,939,307 shares of company stock valued at $16,202,116. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock valued at $128,000 after purchasing an additional 2,402 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after acquiring an additional 3,293 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company’s stock worth $530,000 after acquiring an additional 3,305 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of iTeos Therapeutics by 25.1% during the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock worth $103,000 after acquiring an additional 3,468 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of iTeos Therapeutics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 644,901 shares of the company’s stock worth $4,954,000 after acquiring an additional 4,551 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.